| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/11/2003 | US20030171553 Tumour necrosis factor binding ligands |
| 09/11/2003 | US20030171551 Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
| 09/11/2003 | US20030171496 Drug delivery compositions and medical devices containing block copolymer |
| 09/11/2003 | US20030171437 Pharmaceutical composition |
| 09/11/2003 | US20030171430 Dissolving in iodinated poppyseed oil fatty ester |
| 09/11/2003 | US20030171429 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues |
| 09/11/2003 | US20030171419 Pharmaceutical compositions comprising fluvastatin |
| 09/11/2003 | US20030171416 Nordihydroguaiaretic acid; anticancer agents, viricides |
| 09/11/2003 | US20030171401 Insertion drug delivery device containing fentanyl |
| 09/11/2003 | US20030171391 Headaches; muscular disorders; antiinflammatory agents |
| 09/11/2003 | US20030171388 Vitamins injected into gel spheres of various colors; mixture of orotic acid and carnitine |
| 09/11/2003 | US20030171344 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 09/11/2003 | US20030171343 Preparation for external use is a patch that a pressure-sensitive adhesive layer containing a steroidal antiphlogistic is provided on a support, and the pressure-sensitive adhesive layer further contains a |
| 09/11/2003 | US20030171340 Treating antibiotic-resistant infections with a metal complex of tetracycline, glycylcycline, or quinolone antibiotics, or administering a metal compound and the antibiotic together for in situ formation of the complex |
| 09/11/2003 | US20030171337 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and |
| 09/11/2003 | US20030171334 Treatment of prostate cancer |
| 09/11/2003 | US20030171333 Pharmaceutical composition containing at least a polymer combined with or conjugated to at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof |
| 09/11/2003 | US20030171329 Stable compositions comprising tezacitabine |
| 09/11/2003 | US20030171307 Equilibrium mixture of azalide isomers, water, and one or more acids, and methods for preparing such compositions, are disclosed. The antibiotic compositions can be advantageously stabilized by adding one or more water-miscible co-solvents |
| 09/11/2003 | US20030171299 Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by |
| 09/11/2003 | US20030171298 Retroinverso polypeptides that mimic or inhibit thrombospondin |
| 09/11/2003 | US20030171296 Pharmaceutical formulations for sustained drug delivery |
| 09/11/2003 | US20030171285 Chemically-modified human growth hormone conjugates |
| 09/11/2003 | US20030171281 Therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, in the treatment of microorganism-caused infections, which infections may be systemic, such as a |
| 09/11/2003 | US20030171267 Albumin fusion proteins |
| 09/11/2003 | US20030171264 Microemulsion preconcentrate; reduced toxicity but high bioavailability; contain cyclosporin A analog ISATx247 (Voclosporin), tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), medium chain triglyceride (MCT) oil, a Tween" emulsifier, and ethanol |
| 09/11/2003 | US20030171262 Residue of a drug compound such as antineoplastic agents and a carboxy(C1-4) alkyldextran polyalcohol obtained by treating a dextran under conditions that enable substantially complete polyalcoholization are bound to each other by means of a |
| 09/11/2003 | US20030171261 Fucosyl gm1-klh conjugate vaccine against small cell lung cancer |
| 09/11/2003 | US20030171260 Compositions and methods utilizing hydroxamates to scavenge oxidant toxins |
| 09/11/2003 | US20030171257 Method and related composition employing nanostructures |
| 09/11/2003 | US20030170893 Nanocapsule encapsulation system and method |
| 09/11/2003 | US20030170891 RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| 09/11/2003 | US20030170840 Genomic mammary amyloid a sequence |
| 09/11/2003 | US20030170743 Determination sensitivity; administering gene moderators |
| 09/11/2003 | US20030170697 Detection and treatment of infections with immunoconjugates |
| 09/11/2003 | US20030170334 Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations |
| 09/11/2003 | US20030170327 Vitamin and zinc monomethionine compositions |
| 09/11/2003 | US20030170324 Microencapsulated oil |
| 09/11/2003 | US20030170315 Bioactivation of iron salt, especially an ferric ferrous salt, by adding a magnesium salt (MgCl2); useful as a medicine to treat diseases such as diabetes, freshness preservative agent, and animal and plant growth promoter |
| 09/11/2003 | US20030170314 Carrier; and an atomically disordered, nanocrystalline metal-containing (especially silver) compound; may be antimicrobial, antinflammatory, anticancer, proapoptosis and/or an MMP modulating |
| 09/11/2003 | US20030170312 Method for coating solid particles with a thermofusible agent, and resulting coated solid particles |
| 09/11/2003 | US20030170309 Pharmaceutical compositions containing polymer and drug assemblies |
| 09/11/2003 | US20030170307 Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| 09/11/2003 | US20030170304 Delivers an active ingredient in a pulsed or bimodal manner. |
| 09/11/2003 | US20030170303 That has low water solubility such as celecoxib; and a release- extending polymer. |
| 09/11/2003 | US20030170299 Therapeutic methods for acute myeloid leukemia |
| 09/11/2003 | US20030170298 Treating oily bodies in cosmetically acceptable solvents with lecithins and/or phospholipids. |
| 09/11/2003 | US20030170297 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin |
| 09/11/2003 | US20030170296 Transdermal drug delivery system |
| 09/11/2003 | US20030170295 Hydrogel composition for transdermal drug delivery |
| 09/11/2003 | US20030170289 Injectable depot compositions and uses thereof |
| 09/11/2003 | US20030170286 Codrug with at least two constituent moieties cleavably linked covalently to one another; dimensioned to position two radiation seeds a predetermined distance apart. |
| 09/11/2003 | US20030170280 Particles comprising porous and/ or polycrystalline silicon or multilayer porous silicon oxide mirrors; sunscreen agents |
| 09/11/2003 | US20030170279 Emulsion vehicle for poorly soluble drugs |
| 09/11/2003 | US20030170278 Includes a microcapsule, a semipermeable membrane capable of eliciting a fibrotic response from a higher order mammal, and a second matrix being of a thickness sufficient to prevent nucleation of fibrosis when implanted |
| 09/11/2003 | US20030170273 Type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules for enhancing the immune response of a coadministered antigen |
| 09/11/2003 | US20030170250 Wound healing agent, antibiotic, antiinflammatory, antioxidant, antiproliferative, immunosuppressant, or anticancer agent linked to an entity covalently reactive with a functionality on fixed blood components |
| 09/11/2003 | US20030170229 Epitopes or mimotopes derived from the C epsilon 3 or C epsilon 4 domains of IgE; prevention or amelioration of allergic disease. |
| 09/11/2003 | US20030170218 Fungicide and method for producing the same |
| 09/11/2003 | US20030170217 Bifidobacterium in the treatment of inflammatory disease |
| 09/11/2003 | US20030170216 SYN3 compositions and methods |
| 09/11/2003 | US20030170215 Encapsulating a cell culture of propagating pancreatic cells; inserting the encapsulated cells into the mammal permitting the cells to mature to insulin secreting cells |
| 09/11/2003 | US20030170207 For therapy of viral, tumorous and immune diseases |
| 09/11/2003 | US20030170206 Interferon beta-like molecules |
| 09/11/2003 | US20030170204 To enhance in vivo tumour regression activity of the TNF |
| 09/11/2003 | US20030170202 Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
| 09/11/2003 | US20030170201 Polymeric micelle containing cisplatin enclosed therein and use thereof |
| 09/11/2003 | US20030170194 Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid |
| 09/11/2003 | US20030170191 Hair growth stimulant compositions with sustained action |
| 09/11/2003 | US20030170175 Cytotoxic therapy |
| 09/10/2003 | EP1342733A1 Low-substituted cellulose ether powder and production process thereof |
| 09/10/2003 | EP1342732A1 Pharmaceutical carrier comprising low-substituted cellulose ether, for external application |
| 09/10/2003 | EP1342472A1 Analgesic and anti-inflammatory patches for external use containing 4-biphenylylylacetic acid |
| 09/10/2003 | EP1342471A1 Nanocapsules based on polyol polyester, and cosmetic and dermatological compositions containing same |
| 09/10/2003 | EP1342462A1 O/w emulsion composition and method of preparing the same |
| 09/10/2003 | EP1341908A2 Targeted enzyme prodrug therapy |
| 09/10/2003 | EP1341907A2 Target enzymes |
| 09/10/2003 | EP1341821A1 Thermoplastic and water soluble cellulose ether esters |
| 09/10/2003 | EP1341565A2 Drug delivery compositions and coated medical devices |
| 09/10/2003 | EP1341556A2 Drug delivery system |
| 09/10/2003 | EP1341555A2 Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same |
| 09/10/2003 | EP1341551A2 Treatment of posterior capsule opacification |
| 09/10/2003 | EP1341529A2 Hydrolytically unstable compositions |
| 09/10/2003 | EP1341528A1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 09/10/2003 | EP1341527A1 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 09/10/2003 | EP1341526A2 Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| 09/10/2003 | EP1341525A2 Novel process |
| 09/10/2003 | EP1341524A2 Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
| 09/10/2003 | EP1341523A1 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
| 09/10/2003 | EP1341522A2 Microparticles with an improved release profile and method for the production thereof |
| 09/10/2003 | EP1341521A2 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
| 09/10/2003 | EP1341517A1 A skin cream composition |
| 09/10/2003 | EP1341515A1 Water-free skin care formulations comprising micronized urea and method of manufacturing the same |
| 09/10/2003 | EP1341497A2 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 09/10/2003 | EP1253937B1 Use of thrombin derived peptides for the treatment of cardiovascular disorders |
| 09/10/2003 | EP1189600B1 Grf-containing lyophilized pharmaceutical compositions |
| 09/10/2003 | EP1156814B1 Pharmaceuticals, dietary supplements and cosmetic compositions comprising a fatty acid and ginger |
| 09/10/2003 | EP1135139B1 Micronized eplerenone compositions |
| 09/10/2003 | EP1123089B1 Tablet for crunching with masked taste and instant release of active principle and method for making same |
| 09/10/2003 | EP1053029B1 Sterile complex of therapeutic peptide bond to a polysaccharide |